

Table S1 Additional information about participating centres

Country	Number of patients	Investigators	City
France	13	Alexandre Louvet	Lille
Belgium	9	Axel Hittélet	Mons
France	8	Céline Bazille	Caen
Belgium	7	Boris Bastens	Liège
Belgium	7	Hans Orlent	Brugge
Belgium	6	Luc Lasser	Brussels
Belgium	4	Peter Stärkel	Brussels
Belgium	3	Xavier Dekoninck	Ottignies
Belgium	3	Sergio Negrin Dastis	Mons
Belgium	2	Jean Delwaide	Liège
Belgium	1	Anja Geerts	Gent
Belgium	1	Chantal de Galocsy	Brussels
Belgium	1	Sven Francque	Antwerpen
Belgium	1	Phillippe Langlet	Brussels
Belgium	1	Virginie Putzeys	Liège
Belgium	1	Hendrik Reynaert	Brussels




Figure S1 Histogram of screening MELD score with the frequency distribution of values in improvers and non-improvers (A) and in alive or dead patients (B) at 3 months. MELD, model for end-stage liver disease.

Table S2 Comparison of clinical, biological and histological characteristics according to the 3-month survival

Characteristics at screening	Alive at 3 months (n=31)	Dead at 3 months (n=26)	P value
Clinical			
Age (years)	49.79±8.35	50.32±9.14	0.82
Male sex	18 [58]	20 [76.9]	0.13
BMI (kg/m ²)	26.10±4.19	28.86±6.52	0.08
Ascites	17 [55]	20 [77]	0.10
Ascites grade			0.003
Grade I	2 [6]	0 [0]	
Grade II–III	15 [48]	20 [77]	
Encephalopathy	7 [23]	9 [35]	0.38
Encephalopathy grade			0.30
Grade I	5 [16]	5 [19]	
Grade II–III	2 [6]	4 [15]	
Biological			
INR	1.74 (1.52–1.93)	1.9 (1.69–2.30)	0.02
Platelets (10 ³ /mL)	153 (108–227)	89 (72–128)	0.002
White blood cell count (/mL)	10,130 (7,550–12,460)	9,350 (6,300–12,255)	0.72
Bilirubin (mg/dL)	14.05±8.2	19.54±11.07	0.04
Creatinine (mg/dL)	0.67 (0.57–0.80)	0.80 (0.61–0.98)	0.08
Albumin (g/L)	26.00 (22.25–28.38)	26.00 (23.00–29.00)	0.92
Sodium (mEq/L)	135.58±4.45	132.80±5.96	0.06
AST (U/L)	129.58±56.23	122.77±49.04	0.74
GGT (U/L)	247.00 (161.00–463.00)	144.00 (67.00–222.00)	<0.001
MELD score	21.81±2.99	25.50±5.00	0.002
MDF	48.00 (36.28–63.22)	63.92 (52.00–78.50)	0.005
Histological			
Biopsies length (mm)	14.64 (10.61–25.39)	11.12 (8.39–20.07)	0.17
Biopsies fields (×400)	24.0 (15.5–42.5)	18.5 (9.5–26)	0.051
Portal tracts on biopsy	6 (3–11)	4 (3–11)	0.46
Metavir fibrosis score			0.68
Grade II	2 [6.4]	1 [3.9]	
Grade III	7 [22.6]	5 [19.2]	
Grade IV	22 [71]	20 [76.9]	
K7 area (%)	1.91 (0.97–5.02)	3.82 (1.64–6.72)	0.17
Proliferative K7 by field	0.75 (0.20–1.89)	0.70 (0.09–2.05)	0.86
Proliferative K7 (DR) by field	0.33 (0.05–0.89)	0.19 (0.00–0.98)	0.39
Proliferative K7 (IPC) by field	0.19 (0.04–0.41)	0.13 (0.00–0.49)	0.83
Proliferative K7 (IH) by field	0.16 (0.04–0.32)	0.15 (0.02–0.60)	0.49
Proliferative hepatocytes by field	6.15 (1.04–9.64)	5 (1.66–10.92)	0.76
Total CD68 area (%)	1.62 (0.70–2.58)	1.37 (1.10–3.70)	0.40

Data are presented as mean ± standard deviation, n [%] or median (interquartile range, 25th–75th percentile). Data are presented for the entire cohort (n=57). Missing data for 3 patients for the BMI, 5 patients for the albumin level, 1 patient for the sodium level, 1 patient for the white blood cell count and 1 patient for the GGT level. Student *t*-test was used when the distribution of the data was normal and Mann-Whitney test in case of non-normal distribution. BMI, body mass index; INR, international normalized ratio; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; MELD, model for end-stage liver disease; MDF, Maddrey discriminant function; K7, keratin 7; DR, ductular reaction; IPC, intermediate progenitor cells; IH, intermediate hepatocytes; CD68, cluster of differentiation 68.